Top 100 - Preparations

Human recombinant cysteine depleted interferon- beta muteins

US4588585 (A), filed Fri Sep 28 00:00:00 CDT 1984 , published Tue May 13 00:00:00 CDT 1986 - CETUS CORP

Muteins of biologically active proteins such as IFN- beta and IL-2 in which cysteine residues that are not essential to biological activity have been deleted or replaced with other amino acids to eliminate sites for intermolecular crosslinking or incorrect...

Methods for treating systemic lupus erythematosus using anti-TNF antibodies and fragments thereof

US7128908 (B2), filed Tue Jul 12 00:00:00 CDT 2005 , published Tue Oct 31 00:00:00 CST 2006 - UNIV NEW YORK

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...

PRO1571 polypeptides

US7332573 (B2), filed Thu Jun 27 00:00:00 CDT 2002 , published Tue Feb 19 00:00:00 CST 2008 - GENENTECH INC

The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptid...

Suppression of premature labor by use of aromatase inhibitors

US4500523 (A), filed Mon Apr 09 00:00:00 CST 1984 , published Tue Feb 19 00:00:00 CST 1985 - CORNELL RES FOUNDATION INC

This invention relates to the use of aromatase inhibitors to suppress premature labor in mammals by administering an aromatase inhibitor preferably 4-hydroxy-4-androstene-3,17-dione or 4-acetoxy-4-androstene-3,17-dione to a pregnant mammal.

Non-a, non-b, non-c, non-c, non-d, non-e hepatitis reagents and methods for their use

US6720166 (B2), filed Mon Jun 05 00:00:00 CDT 1995 , published Tue Apr 13 00:00:00 CDT 2004 - ABBOTT LAB

Hepatitis GB Virus (HGBV) nucleic acid and amino acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HGBV nucleic acid or amino acid sequences, HGBV immunogenic particles, and antibodies which specifically bind to...

Highly purified gonadotropin compositions and process for preparing them

US7022822 (B1), filed Tue Jan 15 00:00:00 CST 2002 , published Tue Apr 04 00:00:00 CDT 2006 - INST MASSONE S A

Purification process of humanPurification process of human urinary gonadotropins of high biological activity and chemical purity absolutely free of foreign contaminating materials derived from the use of biological reagents or chromatography dyes, from crude...

Vectors and compounds for expression of human protein C

US4775624 (A), filed Fri Feb 08 00:00:00 CST 1985 , published Tue Oct 04 00:00:00 CDT 1988 - LILLY CO ELI

The present invention comprises novel DNA compounds which encode human protein C activity. A variety of eukaryotic and prokaryotic recombinant DNA expression vectors have been constructed that comprise the novel protein C activity-encoding DNA and drive...

Treatment of human viral infections

US4724232 (A), filed Tue Sep 17 00:00:00 CDT 1985 , published Tue Feb 09 00:00:00 CST 1988 - BURROUGHS WELLCOME CO

Treatment of AIDS or humans carrying or infected with the AIDS virus or having antibodies to the AIDS virus is disclosed using the compound 3'-azido-3'-deoxythymidine or a pharmaceutically acceptable basic salt thereof. Also disclosed is the use of the...

Methods of inhibiting TNFalpha in patients with neoplastic disease

US7214376 (B2), filed Fri Dec 07 00:00:00 CST 2001 , published Tue May 08 00:00:00 CDT 2007 - CENTOCOR INC

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...

Methods of treating psoriasis with anti-TNF antibodies

US7335358 (B2), filed Mon Dec 04 00:00:00 CST 2006 , published Tue Feb 26 00:00:00 CST 2008 - UNIV NEW YORK

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...

Methods of treating rheumatoid arthritis with anti-TNF antibodies

US7138118 (B2), filed Thu Dec 08 00:00:00 CST 2005 , published Tue Nov 21 00:00:00 CST 2006 - UNIV NEW YORK

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...

Transgenic plants expressing assembled secretory antibodies

US6417429 (B1), filed Wed Nov 25 00:00:00 CST 1998 , published Tue Jul 09 00:00:00 CDT 2002 - SCRIPPS RESEARCH INST

The present invention relates to expression and assembly of foreign multimeric proteins-e.g., antibodies-in plants, as well as to transgenic plants that express such proteins. In one of several preferred embodiments, the generation and assembly of functional...

Creating an aerosolized formulation of insulin

US5915378 (A), filed Fri Oct 27 00:00:00 CDT 1995 , published Tue Jun 29 00:00:00 CDT 1999 - ARADIGM CORP

Devices, packaging and methodology for efficiently and repeatably creating aerosolized bursts of an insulin containing formulation are disclosed. Devices are hand-held, self-contained units which are automatically actuated at the same release point in a...

Systems and methods for delivering drugs to selected locations within the body

US7094230 (B2), filed Tue Dec 16 00:00:00 CST 2003 , published Tue Aug 22 00:00:00 CDT 2006 - MEDTRONIC VASCULAR INC

An implantable reservoir device ( 400 ) including an enclosed membrane ( 408 ) on an expandable frame ( 402 ) that defines a reservoir ( 410 ) and includes a porous region ( 418 ). The reservoir device ( 400 ) may be deployed and expanded within a blood...

Prodrugs activated by targeted catalytic proteins

US6702705 (B1), filed Wed Feb 22 00:00:00 CST 1995 , published Tue Mar 09 00:00:00 CST 2004 - IGEN INT INC

Catalytic antibodies are disclosed. The catalytic antibodies are specific for prodrug compounds. The catalytic antibodies enhance cleavage of an active drug moiety from a prodrug residue, thereby activating the drug.

PRO4400 polypeptides

US7361732 (B2), filed Wed May 08 00:00:00 CDT 2002 , published Tue Apr 22 00:00:00 CDT 2008 - GENENTECH INC

The present invention is directed to novel polypeptide and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptide...

Aminoacid derivatives as antihypertensives

US4374829 (A), filed Tue Feb 17 00:00:00 CST 1981 , published Tue Feb 22 00:00:00 CST 1983 - MERCK CO INC

The invention relates to new carboxyalkyl dipeptide derivatives and related compounds which are useful as antihypertensives.

Backbone polysubstituted chelates for forming a metal chelate-protein conjugate

US5246692 (A), filed Thu Aug 22 00:00:00 CDT 1991 , published Tue Sep 21 00:00:00 CDT 1993 - US HEALTH

New polysubstituted diethylenetriaminepentaacetic acid chelates and protein conjugates of the same are described together with the methods of preparing such compounds. A method of delivering radiolabelled compound of the present invention to a target site...

Iron oxide coated substrates

US5352517 (A), filed Tue Jan 18 00:00:00 CST 1994 , published Tue Oct 04 00:00:00 CDT 1994 - ENSCI INC

Processes for coating substrates, in particular substrates including shielded surfaces, with iron oxide-containing coatings are disclosed. Such processes comprise contacting a substrate with an iron oxide precursor, preferably maintaining the precursor coated...

Process for making cellulase-free xanthan gum

US4259477 (A), filed Mon Jun 04 00:00:00 CDT 1979 , published Tue Mar 31 00:00:00 CST 1981 - MERCK CO INC

Cellulase in xanthan gum can be completely destroyed by treating xanthan gum beer with about 0.08 to 0.1% alkali metal hypochlorite followed by heat treatment.

Anticalculus oral composition

US4627977 (A), filed Fri Sep 13 00:00:00 CDT 1985 , published Tue Dec 09 00:00:00 CST 1986 - COLGATE PALMOLIVE CO

An oral composition such as a toothpaste (including gel or cream), mouthwash, lozenge, chewing gum or tooth powder containing a calculus-inhibiting amount of a linear molecularly dehydrated polyphosphate salt and, to inhibit enzymatic hydrolysis of said...

Preparations containing methylsulfonylmethane and methods of use and purification

US4477469 (A), filed Fri Jun 26 00:00:00 CDT 1981 , published Tue Oct 16 00:00:00 CDT 1984 - HERSCHLER R J

Preparations containing methylsulfonylmethane (MSM) for administration to the skin, nails, other tissue and/or body fluids of a human or other animal subject are disclosed. Such compositions soften skin, strengthen nails and provide other benefits when applied...

Benzofurylpiperazines and benzofurylhomopiperazines: serotonin agonists

US6967201 (B1), filed Mon May 06 00:00:00 CDT 2002 , published Tue Nov 22 00:00:00 CST 2005 - LILLY CO ELI

The present invention provides serotonergic benzofurylpiperazines of Formula I: where: A is a piperazine of formula: and R, RSUP1/SUP, RSUP2/SUP, RSUP3/SUP, RSUP4/SUP, RSUP5/SUP, RSUP5'/SUP, RSUP6/SUP, RSUP6'/SUP, RSUP7/SUP, RSUP7'/SUP, RSUP8/SUP, and...

Pharmaceutical composition for inhibiting the growth of viruses and cancers

US5665713 (A), filed Wed Apr 12 00:00:00 CDT 1995 , published Tue Sep 09 00:00:00 CDT 1997 - PROCTER GAMBLE

This invention is a pharmaceutical composition that inhibits the growth of cancers and tumors in mammals, particularly in human and warm blooded animals. The composition is also effective against viruses. The composition contains N-phosphonoglycine derivatives...

Vaccine for clostridium botulinum neurotoxin

US5919665 (A), filed Thu Mar 16 00:00:00 CST 1995 , published Tue Jul 06 00:00:00 CDT 1999 - OPHIDIAN PHARM INC

The present invention includes recombinant proteins derived from Clostridium botulinum toxins. In particular, soluble recombinant Clostridium botulinum type A toxin proteins are provided. Methods which allow for the isolation of recombinant proteins free of...

Therapeutic uses of arglabin in combination with other chemotherapy agents

US6770673 (B1), filed Mon Feb 01 00:00:00 CST 1999 , published Tue Aug 03 00:00:00 CDT 2004 - PARACURE INC

Compositions and kits containing a first chemotherapeutic agent that includes arglabin or a derivative thereof and a second chemotherapeutic agent are described. The compositions and kits are effective for treating cancer in a human patient. Methods for...

Subsaturated nicotine transdermal therapeutic system

US6165497 (A), filed Fri Mar 01 00:00:00 CST 1991 , published Tue Dec 26 00:00:00 CST 2000 - ALZA CORP

Rate controlled transdermal nicotine delivery systems are disclosed which utilize an in-line adhesive to maintain the systems on the skin. The initial equilibrated concentration of nicotine in the nicotine reservoir and the adhesive is below saturation,...

Composition for inducing humoral anergy to an immunogen comprising a T cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic valency platform molecule

US6060056 (A), filed Wed Sep 08 00:00:00 CDT 1993 , published Tue May 09 00:00:00 CDT 2000 - JOLLA PHARMA

Conjugates of nonimmunogenic valency platform molecules and analogs of immunogens that possess the specific B cell binding ability of the immunogen but lack T cell epitopes and which, when introduced into individuals, induce humoral anergy to the immunogen are...

Directed evolution of novel binding proteins

US5837500 (A), filed Mon Apr 03 00:00:00 CDT 1995 , published Tue Nov 17 00:00:00 CST 1998 - DYAX CORP

In order to obtain a novel binding protein against a chosen target, DNA molecules, each encoding a protein comprising one of a family of similar potential binding domains and a structural signal calling for the display of the protein on the outer surface of a...

Growth hormone variants

US6780613 (B1), filed Wed Jun 07 00:00:00 CDT 1995 , published Tue Aug 24 00:00:00 CDT 2004 - GENENTECH INC

The invention provides methods for the systematic analysis of the structure and function of polypeptides by identifying active domains which influence the activity of the polypeptide with a target substance. Such active domains are determined by substituting...

Methods of treatment of fistulas in Crohn's disease with anti-TNF antibodies

US7223396 (B2), filed Thu Dec 12 00:00:00 CST 2002 , published Tue May 29 00:00:00 CDT 2007 - UNIV NEW YORK

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...

CTLA4/CD28Ig hybrid fusion proteins and uses thereof

US6090914 (A), filed Fri Apr 15 00:00:00 CDT 1994 , published Tue Jul 18 00:00:00 CDT 2000 - SQUIBB BRISTOL MYERS CO

The invention identifies the CTLA4 receptor as a ligand for the B7 antigen. The complete amino acid sequence encoding human CTLA4 receptor gene is provided. Methods are provided for expressing CTLA4 as an immunoglobulin fusion protein, for preparing hybrid...

Methods for treating sarcoidosis using anti-TNF antibodies and fragments thereof

US7135179 (B2), filed Wed Jul 13 00:00:00 CDT 2005 , published Tue Nov 14 00:00:00 CST 2006 - UNIV NEW YORK

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...

Methods of treating inflammation associated with viral infection with anti-TNF antibodies

US7169386 (B1), filed Thu Jan 10 00:00:00 CST 2002 , published Tue Jan 30 00:00:00 CST 2007 - CENTOCOR INC

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...

Topical steroid cream formulations

US7312207 (B2), filed Wed May 19 00:00:00 CDT 2004 , published Tue Dec 25 00:00:00 CST 2007 - TARO PHARMACEUTICALS NORTH AME

Disclosed is a novel mometasone furoate cream formulation for topical administration in a oleaginous base containing propylene glycol. This cream is a cosmetically elegant preparation of mometasone that is both stable and bioeffective.

Formulations and methods of use of 2,2'-dithio-bis-ethane sulfonate

US5902610 (A), filed Fri Nov 03 00:00:00 CST 1995 , published Tue May 11 00:00:00 CDT 1999 - BIONUMERIK PHARMACEUTICALS INC

This invention describes novel formulations containing a water soluble disulfide, 2,2'-dithio-bis-ethane sulfonate, with or without cis-diammine dichloro platinum present in the same formulation, wherein the parenteral or oral administration of 2,2'-dithio-bis...

Biodegradable in-situ forming implants and methods of producing the same

US5733950 (A), filed Mon Sep 25 00:00:00 CDT 1995 , published Tue Mar 31 00:00:00 CST 1998 - ATRIX LAB INC

A biodegradable polymer is provided for use in providing syringeable, in-situ forming, solid biodegradable implants for animals. The polymer is placed into the animal in liquid form and cures to form the implant in-situ. A thermoplastic system to form said...

PRO1758 polypeptides

US7291704 (B2), filed Thu Jun 27 00:00:00 CDT 2002 , published Tue Nov 06 00:00:00 CST 2007 - GENENTECH INC

The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptid...

Delivery of antiemetics through an inhalation route

US7014841 (B2), filed Wed Mar 31 00:00:00 CST 2004 , published Tue Mar 21 00:00:00 CST 2006 - ALEXZA PHARMACEUTICALS INC

The present invention relates to the delivery of antiemetics through an inhalation route. Specifically, it relates to aerosols containing antiemetics that are used in inhalation therapy. In a method aspect of the present invention, an antiemetic is delivered...

Methods of inhibiting or neutralizing TNFalpha in patients with tissue injury

US7404955 (B2), filed Tue Aug 02 00:00:00 CDT 2005 , published Tue Jul 29 00:00:00 CDT 2008 - UNIV NEW YORK

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...

Methods of treating TNF alpha -mediated disease using chimeric anti-TNF antibodies

US5919452 (A), filed Fri Feb 04 00:00:00 CST 1994 , published Tue Jul 06 00:00:00 CDT 1999 - UNIV NEW YORK

Treatment of tumor necrosis factor, TNF, mediated pathologies is provided by administering anti-TNF compounds, such as anti-TNF antibodies and anti-TNF peptides, which compounds are specific for tumor necrosis factor- alpha (TNF alpha ) or tumor necrosis...

Secreted and transmembrane polypeptides and nucleic acids encoding the same

US7223838 (B2), filed Fri May 03 00:00:00 CDT 2002 , published Tue May 29 00:00:00 CDT 2007 - GENENTECH INC

The present invention is directed to novel polypeptides and to nucleic acid molecules encoding those polypeptides. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptid...

Process for coating a substrate with iron oxide and uses for coated substrates

US5290589 (A), filed Mon Aug 12 00:00:00 CDT 1991 , published Tue Mar 01 00:00:00 CST 1994 - ENSCI INC

Processes for coating substrates, in particular substrates including shielded surfaces, with iron oxide-containing coatings are disclosed. Such processes comprise contacting a substrate with an iron oxide precursor, preferably maintaining the precursor coated...

Method and apparatus for administration of contrast agents for use in magnetic resonance arteriography

US6889072 (B2), filed Thu Jul 05 00:00:00 CDT 2001 , published Tue May 03 00:00:00 CDT 2005

The present invention is a method and apparatus for providing preferential enhancement of an artery of interest relative to adjacent veins and background tissue. The method and apparatus adapts the timing of a maximum or substantially elevated rate of infusion...

Recycle process for the production of low-cost soluble collagen

US5460967 (A), filed Fri May 27 00:00:00 CDT 1994 , published Tue Oct 24 00:00:00 CDT 1995 - RANPAK CORP

The invention includes a method that produces a low cost aqueous solution of solubilized collagen by the steps of: (a) providing an aqueous ground slurry of insoluble collagen and adjusting the pH of said slurry to obtain activity for a proteolytic enzyme...

Recycle process for the production of low-cost soluble collagen

US5460967 (B1), filed Fri May 27 00:00:00 CDT 1994 , published Tue Mar 10 00:00:00 CST 1998 - RANPAK CORP CONCORD

HIV immunoassays using gag polypeptides

US6458527 (B1), filed Mon Jun 28 00:00:00 CDT 1993 , published Tue Oct 01 00:00:00 CDT 2002 - CHIRON CORP

Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to...

Lactalbumin production process

US7053185 (B1), filed Tue Aug 15 00:00:00 CDT 2000 , published Tue May 30 00:00:00 CDT 2006 - HAMLET PHARMA AB

A method for producing an oligomeric form of alpha-lactalbumin which is in the molten globule-like state is described. The method suitably comprises exposing a source of alpha-lactalbumin in which the alpha-lactalbumin is preferably in the molten globule-like...

Calcium phosphate cement, use and preparation thereof

US7094282 (B2), filed Wed Apr 16 00:00:00 CDT 2003 , published Tue Aug 22 00:00:00 CDT 2006 - CALCITEC INC

A calcium phosphate cement suitable for use in dental and bone prosthesis is disclosed, which include calcium phosphate particles having a diameter of 0.05 to 100 microns, wherein said calcium phosphate particles on their surfaces have whiskers or fine...

Method of stimulating epithelial cells using keratinocyte growth factor (KGF) and method of inhibiting KGF activity

US6833132 (B1), filed Wed May 31 00:00:00 CDT 1995 , published Tue Dec 21 00:00:00 CST 2004 - US HEALTH

Discoveries are disclosed that show particular aspects of recombinant DNA technology can be used sucessfully to produce hitherto unknown human keratinocyte growth factor (KGF) protein free of other polypeptides. These proteins can be produced in various...

Human immunodeficiency virus (HIV) nucleotide sequences

US7393949 (B1), filed Wed May 17 00:00:00 CDT 1995 , published Tue Jul 01 00:00:00 CDT 2008 - NOVARTIS VACCINES DIAGNOSTIC

Polynucleotide sequences are provided for the diagnosis of the presence of retroviral infection in a human host associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome, for expression of polypeptides and use of the polypeptides to...

Substituted pyrazolyl benzenesulfonamides for the treatment of inflammation

US5760068 (A), filed Fri Sep 06 00:00:00 CDT 1996 , published Tue Jun 02 00:00:00 CDT 1998 - SEARLE CO

PCT No. PCT/US94/12720 Sec. 371 Date Sep. 6, 1996 Sec. 102(e) Date Sep. 6, 1996 PCT Filed Nov. 14, 1994 PCT Pub. No. WO95/15316 PCT Pub. Date Jun. 8, 1995A class of pyrazolyl benzenesulfonamide compounds is described for use in treating inflammation and...

Delivery of beta-blockers through an inhalation route

US7018620 (B2), filed Mon Feb 09 00:00:00 CST 2004 , published Tue Mar 28 00:00:00 CST 2006 - ALEXZA PHARMACEUTICALS INC

The present invention relates to the delivery of atenolol, pindolol, esmolol, propranolol, or metoprolol through an inhalation route. Specifically, it relates to aerosols containing atenolol, pindolol, esmolol, propranolol, or metoprolol that are used in...

Delivery of antihistamines through an inhalation route

US7094392 (B2), filed Tue Dec 30 00:00:00 CST 2003 , published Tue Aug 22 00:00:00 CDT 2006 - ALEXZA PHARMACEUTICALS INC

The present invention relates to the delivery of antihistamines through an inhalation route. Specifically, it relates to aerosols containing antihistamines that are used in inhalation therapy. In a method aspect of the present invention, an antihistamine is...

Novel steroids

US4386085 (A), filed Fri Jan 08 00:00:00 CST 1982 , published Tue May 31 00:00:00 CDT 1983 - ROUSSEL UCLAF

Novel 19-nor steroids and 19-nor-D-homo-steroids of the formula IMAGE I' wherein R1 is an organic radical of 1 to 18 carbon atoms containing at least one atom selected from the group consisting of nitrogen, phosphorous and silicon with the atom immediately...

Immunogenic conjugates

US4673574 (A), filed Tue Jul 05 00:00:00 CDT 1983 , published Tue Jun 16 00:00:00 CDT 1987 - ANDERSON PORTER W

An immunogenic conjugate which is the reductive amination product of an immunogenic capsular polymer fragment having a reducing end and derived from a bacterial capsular polymer of a bacterial pathogen, and a bacterial toxin or toxoid. The invention also...

Cationic amphiphiles for intracellular delivery of therapeutic molecules

US5650096 (A), filed Fri Dec 09 00:00:00 CST 1994 , published Tue Jul 22 00:00:00 CDT 1997 - GENZYME CORP

Novel cationic amphiphiles are provided that facilitate transport of biologically active molecules into cells. Typically, the amphiphiles contain lipophilic groups derived from steroids or from mono or dialkylamines, and two cationic groups, protonatable at...

Pharmaceutical composition for inhibiting the growth of cancers

US6025377 (A), filed Fri Aug 21 00:00:00 CDT 1998 , published Tue Feb 15 00:00:00 CST 2000 - PROCTER GAMBLE

A pharmaceutical composition that inhibits the growth of tumors and cancers in mammals that comprises a material is disclosed. The particular material used is a 1H-1,2,4-triazole derivative. These compounds can also be used to treat viral infections.

Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis

US5003080 (A), filed Wed Feb 01 00:00:00 CST 1989 , published Tue Mar 26 00:00:00 CST 1991 - WARNER LAMBERT CO

Composition and method for treating the effects of diseases and maladies

US6759062 (B2), filed Fri Jan 05 00:00:00 CST 2001 , published Tue Jul 06 00:00:00 CDT 2004 - BIOSELECT INNOVATIONS INC

An improved medicinal composition includes an effective amount of an antihistamine pharmaceutical and an effective amount of a nutraceutical in a pharmaceutically acceptable base. At least one of the pharmaceutical and the nutraceutical treats a condition...

DNA encoding novel polypeptide having Factor Xa inhibitory activity

US5783421 (A), filed Tue Jun 06 00:00:00 CDT 1995 , published Tue Jul 21 00:00:00 CDT 1998 - BIO TECHNOLOGY GENERAL CORP

A novel polypeptide derived from the leech Hirudo medicinalis was found to be able to inhibit Factor Xa thereby reducing the extent of blood coagulation. The polypeptide is useful in treating conditions of excessive blood coagulation. A recombinant organism...

Dense star polymer

US4558120 (A), filed Tue Dec 27 00:00:00 CST 1983 , published Tue Dec 10 00:00:00 CST 1985 - DOW CHEMICAL CO

Dense star polymers having terminal group densities greater than conventional star polymers exhibit greater and more uniform reactivity than their corresponding conventional star polymers. For example, a third generation, amine-terminated polyamidoamine dense...

Stent lining

US7371257 (B2), filed Tue Nov 23 00:00:00 CST 2004 , published Tue May 13 00:00:00 CDT 2008 - BOSTON SCIENT SCIMED INC

The invention features a catheter assembly and methods for delivering a hydrogel-lined stent to a body lumen, and methods for lining a stent with a hydrogel. The assembly includes a catheter which has a balloon at least a portion of which is coated with a...

Delivery of nonsteroidal antiinflammatory drugs through an inhalation route

US7070761 (B2), filed Fri Dec 12 00:00:00 CST 2003 , published Tue Jul 04 00:00:00 CDT 2006 - ALEXZA PHARMACEUTICALS INC

The present invention relates to the delivery of nonsteroidal antiinflammatory drugs (NSAIDs) through an inhalation route. Specifically, it relates to aerosols containing NSAIDs that are used in inhalation therapy. In a method aspect of the present invention,...

Methods and compositions using fibrin monomer to make a fibrin sealant

US5750657 (A), filed Mon Oct 18 00:00:00 CDT 1993 , published Tue May 12 00:00:00 CDT 1998 - SQUIBB BRISTOL MYERS CO

The subject invention relates to methods and compositions using nondynamic fibrin monomer which is selectively converted to a fibrin polymer which serves as the fibrin sealant.

Delivery of compounds for the treatment of migraine through an inhalation route

US7005121 (B2), filed Fri Dec 12 00:00:00 CST 2003 , published Tue Feb 28 00:00:00 CST 2006 - ALEXZA PHARMACEUTICALS INC

The present invention relates to the delivery of a migraine headache drug through an inhalation route. Specifically, it relates to aerosols containing a migraine headache drug that are used in inhalation therapy. In a method aspect of the present invention, a...

Methods of inhibiting TNFalpha activity in the blood of a patient

US7425330 (B2), filed Mon Oct 16 00:00:00 CDT 2006 , published Tue Sep 16 00:00:00 CDT 2008 - UNIV NEW YORK

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...

Conotoxins I

US5700778 (A), filed Fri Jun 02 00:00:00 CDT 1995 , published Tue Dec 23 00:00:00 CST 1997 - SALK INST FOR BIOLOGICAL STUDI

Substantially pure conotoxins are provided which inhibit synaptic transmissions at the neuromuscular junctions and which are useful both in vivo and in assays because they specifically target particular receptors, such as the acetylcholine receptor, and ion...

Tetrapeptide

US4792525 (A), filed Mon Jun 17 00:00:00 CDT 1985 , published Tue Dec 20 00:00:00 CST 1988 - JOLLA CANCER RES FOUND

The peptide X-Arg-Gly-Asp-R-Y wherein X is H or at least one amino acid and Y is OH or at least one amino acid, and R is an amino acid selected from Thr or Cys, or other amino acid, having the same cell-attachent activity as fibronectin and the peptide...

Hair styling stick containing polyethylene glycols of different molecular weights

US7135166 (B2), filed Fri Apr 19 00:00:00 CDT 2002 , published Tue Nov 14 00:00:00 CST 2006 - WELLA AG

The hair styling stick contains from 30 to 55 percent by weight of one or more polyethylene glycols with a molecular weight of from 2500 to 5000 g/mol; and from 40 to 70 percent by weight of at least one other polyethylene glycol with a molecular weight of...

Anti-tumor agent

US7150870 (B2), filed Thu Sep 04 00:00:00 CDT 2003 , published Tue Dec 19 00:00:00 CST 2006 - COMBI CO

The invention prevents or treats a tumor, inhibiting tumor growth and malignant progression by providing an antitumor agent containing a treated SOD as the active ingredient, especially a melon SOD coated with gliadin. The invention also applies to a method of...

Methods of treating joint inflammation with anti-TNF antibodies

US7166284 (B2), filed Fri Feb 21 00:00:00 CST 2003 , published Tue Jan 23 00:00:00 CST 2007 - CENTOCOR INC

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...

Long-lasting aqueous dispersions or suspensions of pressure-resistant gas-filled microvesicles and methods for the preparation thereof

USRE39146 (E1), filed Wed Jul 15 00:00:00 CDT 1998 , published Tue Jun 27 00:00:00 CDT 2006 - BRACCO INT BV

One can impart outstanding resistance against collapse under pressure to gas-filled microvesicle used as contrast agents in ultrasonic echography by using as fillers gases whose solubility in water, expressed in liter of gas by liter of water under standard...

1,4-Bis(substituted-amino)-5,8-dihydroxy-anthraquinones and leuco bases thereof

US4278689 (A), filed Thu Aug 02 00:00:00 CDT 1979 , published Tue Jul 14 00:00:00 CDT 1981 - AMERICAN CYANAMID CO

This disclosure describes symmetrical 1,4-bis(substituted-amino)-5,8-dihydroxyanthraquinones useful as chelating agents and for inhibiting the growth of transplanted mouse tumors.

Inhaled insulin dosage control delivery enhanced by controlling total inhaled volume

US7028686 (B2), filed Tue Nov 04 00:00:00 CST 2003 , published Tue Apr 18 00:00:00 CDT 2006 - ARADIGM CORP

Dosages of inhaled insulin are controlled within a narrow range by controlling the total volume of air inhaled by a patient. By repeatedly delivering aerosolized insulin with the same total inhaled volume of air, the amount of insulin delivered to the patient...

In Vivo production and delivery of erythropoietin or insulinotropin for gene therapy

US6846676 (B2), filed Tue Jun 08 00:00:00 CDT 1999 , published Tue Jan 25 00:00:00 CST 2005 - TRANSKARYOTIC THERAPIES INC

The invention provides primary and secondary cells that are transfected with a nucleic acid molecule that encodes erythropoietin, clonal or heterogenous strains of such cells, and methods of producing these cell strains.

NANBV diagnostics and vaccines

US6861212 (B1), filed Mon May 15 00:00:00 CDT 1995 , published Tue Mar 01 00:00:00 CST 2005 - CHIRON CORP

A family of cDNA sequences derived from hepatitis C virus (HCV) are provided. These sequences encode antigens which react immunologically with antibodies present in individuals with non-A non-B hepatitis (NANBH), but which are absent from individuals infected...

Pharmaceutical composition

US7144900 (B2), filed Fri Sep 10 00:00:00 CDT 2004 , published Tue Dec 05 00:00:00 CST 2006 - TAKEDA PHARMACEUTICAL

Pharmaceutical composition which comprises an insulin sensitivity enhancer in combination with other antidiabetics differing from the enhancer in the mechanism of action, which shows a potent depressive effect on diabetic hyperglycemia and is useful for...

Methods of using integrin modulators for treatment of inflammation

US6177475 (B1), filed Mon May 12 00:00:00 CDT 1997 , published Tue Jan 23 00:00:00 CST 2001 - BILLINGS PHARMACEUTICALS INC

The invention provides methods of treating inflammatory diseases and conditions by administering an effective amount of an integrin modulating agent, as further defined and specified herein, to an animal suffering from one of the diseases or conditions. The...

Pharmaceutical agents containing acyclovir, fusaric acid and derivatives thereof

US6939884 (B2), filed Tue Dec 03 00:00:00 CST 2002 , published Tue Sep 06 00:00:00 CDT 2005 - NOVACTYL INC

Compositions are provided, which comprise at least one nucleoside analogue inhibitor, pharmaceutically acceptable salts, solvates, or prodrugs thereof and fusaric acid, derivatives, or pharmaceutically acceptable salts thereof. Pharmaceutical compositions...

Canine corona virus vaccine

US4567043 (A), filed Wed Jun 15 00:00:00 CDT 1983 , published Tue Jan 28 00:00:00 CST 1986 - AMERICAN HOME PROD

An efficacious parenterally administered modified live Canine Corona virus vaccine which provides systemic, humoral protection and also protection of the intestinal tract in dogs from infection by virulent Canine Corona virus is produced. A method for...

Modified vaccinia virus

US4603112 (A), filed Wed Dec 08 00:00:00 CST 1982 , published Tue Jul 29 00:00:00 CDT 1986 - HEALTH RESEARCH INC

What are disclosed are methods for modifying the genome of vaccinia virus to produce vaccinia mutants, particularly by the introduction into the vaccinia genome of exogenous DNA; modified vaccinia prepared by such methods; certain DNA sequences and unmodified...

Methylsulfonylmethane and methods of use

US4296130 (A), filed Thu Aug 30 00:00:00 CDT 1979 , published Tue Oct 20 00:00:00 CDT 1981 - HERSCHLER R J

Preparations containing methylsulfonylmethane (MSM) for administration to the skin, nails, other tissue and/or body fluids of a human or other animal subject are disclosed. Such compositions soften skin, strengthen nails and provide other benefits when applied...

Delivery of stimulants through an inhalation route

US7008616 (B2), filed Thu Apr 01 00:00:00 CST 2004 , published Tue Mar 07 00:00:00 CST 2006 - ALEXZA PHARMACEUTICALS INC

The present invention relates to the delivery of stimulants through an inhalation route. Specifically, it relates to aerosols containing stimulants that are used in inhalation therapy. In a method aspect of the present invention, a stimulant is delivered to a...

Delivery of sedative-hypnotics through an inhalation route

US7087216 (B2), filed Tue Jan 27 00:00:00 CST 2004 , published Tue Aug 08 00:00:00 CDT 2006 - ZAFFARONI ALEJANDRO C

The present invention relates to the delivery of sedative-hypnotics through an inhalation route. Specifically, it relates to aerosols containing sedative-hypnotics that are used in inhalation therapy. In a method aspect of the present invention, a sedative-hyp...

Delivery of erectile dysfunction drugs through an inhalation route

US7115250 (B2), filed Tue Dec 30 00:00:00 CST 2003 , published Tue Oct 03 00:00:00 CDT 2006 - ALEXZA PHARMACEUTICALS INC

The present invention relates to the delivery of erectile dysfunction drugs through an inhalation route. Specifically, it relates to aerosols containing erectile dysfunction drugs that are used in inhalation therapy. In a method aspect of the present...

Methods of using ajoene

US5948821 (A), filed Thu Jan 11 00:00:00 CST 1996 , published Tue Sep 07 00:00:00 CDT 1999 - DAVIDSON JOHN B

The progression of infection and other pathologies produced by a viral infection may be inhibited by administering an effective dosage of Ajoene. Additionally, Ajoene has anti-tumor, anti-shock, and antiinflammation effects. In general, Ajoene may be used to...

Solid salts of clavulanic acid

US6031093 (A), filed Thu Apr 06 00:00:00 CDT 1995 , published Tue Feb 29 00:00:00 CST 2000 - SMITHKLINE BEECHAM PLC

A new antibacterially active agent has been isolated from Streptomyces clavuligerus. This new compound which is designated clavulanic acid has the formula (I): In addition to being a broad spectrum antibiotic of medium potency, clavulanic acid and its salts...

Solid salts of clavulanic acid

US6031093 (C1), filed Thu Apr 06 00:00:00 CDT 1995 , published Tue Oct 16 00:00:00 CDT 2001 - SMITHKLINE BEECHAM PLC

MHC conjugates useful in ameliorating autoimmunity

US6451314 (B1), filed Fri Jun 23 00:00:00 CDT 2000 , published Tue Sep 17 00:00:00 CDT 2002 - ANERGEN INC

The present invention is directed to complexes consisting essentially of an isolated MHC component and an autoantigenic peptide associated with the antigen binding site of the MHC component. These complexes are useful in treating autoimmune disease.

Solid pharmaceutical compositions comprising MSM and their production

US4568547 (A), filed Tue Feb 28 00:00:00 CST 1984 , published Tue Feb 04 00:00:00 CST 1986 - HERSCHLER R J

Methylsulfonylmethane (MSM) is useful as a tableting and granulating aid for pharmaceutically active agents, especially those which are unstable in the presence of moisture, mixtures therewith being or formable into free-flowing powders or granules which are...

Anti-TNF antibodies and peptides of human tumor necrosis factor

US6835823 (B2), filed Mon Jan 08 00:00:00 CST 2001 , published Tue Dec 28 00:00:00 CST 2004 - UNIV NEW YORK

Anti-TNF antibodies, fragments and regions thereof which are specific for human tumor necrosis factor-alpha (TNFalpha) and are useful in vivo diagnosis and therapy of a number of TNFalpha-mediated pathologies and conditions, as well as polynucleotides coding...

Nucleic acid encoding anti-IgE antibodies

US7351816 (B2), filed Tue Oct 19 00:00:00 CDT 2004 , published Tue Apr 01 00:00:00 CDT 2008 - GENENTECH INC

The present invention describes IgE antagonists (including variant anti-IgE antibodies) and their use in diagnosis, therapy or prophylaxis of allergic and other IgE-mediated disorders, including asthma, food allergies, hypersensitivity and anaphylactic...

Substituted imidazo thiazoles thiazines, thiazepines and thiazocines

US4376769 (A), filed Fri Jun 19 00:00:00 CDT 1981 , published Tue Mar 15 00:00:00 CST 1983 - SCHERING CORP

Disclosed herein are novel tetrahydro imidazo thiazoles, tetrahydro imidazo thiazines, hexahydro imidazo thiazepines and hexahydro imidazo thiazocines, intermediates for the preparation thereof, methods of using the compounds as anti-inflammatory agents and...

Method for making intermediates useful in synthesis of retroviral protease inhibitors

US6388094 (B1), filed Mon Nov 01 00:00:00 CST 1999 , published Tue May 14 00:00:00 CDT 2002 - SEARLE CO

A synthesis is described for intermediates which are readily amenable to the large scale preparation of hydroxyethylurea-based chiral HIV protease inhibitors. The method includes forming a diastereoselective epoxide from a chiral alpha amino aldehyde.

Simian immunodeficiency virus peptides with antifusogenic and antiviral activities

US6017536 (A), filed Tue Dec 20 00:00:00 CST 1994 , published Tue Jan 25 00:00:00 CST 2000 - TRIMERIS INC

The present invention relates to peptides which exhibit antifusogenic and antiviral activities. The peptides of the invention consist of a 16 to 39 amino acid region of a simian immunodeficiency virus (SIV) protein. These regions were identified through...

Osteogenic devices

US6919308 (B2), filed Tue Dec 17 00:00:00 CST 2002 , published Tue Jul 19 00:00:00 CDT 2005 - STRYKER CORP

Disclosed are (1) osteogenic devices comprising a matrix containing substantially pure natural-sourced mammalian osteogenic protein; (2) DNA and amino acid sequences for novel polypeptide chains useful as subunits of dimeric osteogenic proteins; (3) vectors...

Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis

US7241571 (B2), filed Fri Dec 19 00:00:00 CST 2003 , published Tue Jul 10 00:00:00 CDT 2007 - UNIV CALIFORNIA

5-LO is expressed in the monocyte/macrophages (mono/mac) and foam cells of atherosclerotic lesions and is differentially expressed in CAST and CON6 mice relative to B6 mice. Mice heterozygous for a null mutation of 5-LO, when placed on an LDLR-/- background,...

Extraction methods for preparing thromboplastin reagents

US5426031 (A), filed Tue May 25 00:00:00 CDT 1993 , published Tue Jun 20 00:00:00 CDT 1995 - BAXTER DIAGNOSTICS INC

The Prothrombin Time (PT) is used as a screening test for blood coagulation factor deficiencies and for monitoring oral anti-coagulant therapy using coumadin. Thromboplastin reagents activate the extrinsic pathway of coagulation and are the basis for the...

Process for the synthesis of intermediates useful for the synthesis of tubulin inhibitors

US6951955 (B2), filed Thu Sep 18 00:00:00 CDT 2003 , published Tue Oct 04 00:00:00 CDT 2005 - WYETH CORP

The invention is a process for the preparation of compounds of the Formula I: where RSUB1/SUB, RSUB2/SUB, RSUB3/SUB, RSUB4 /SUBand RSUB5 /SUBare defined in the specification, which are intermediates useful for the preparation of tubulin inhibitors which are...

Top 100 US Patents in Preparations

section a - human necessities > medical or veterinary science; hygiene > preparations for medical, dental, or toilet purposes